Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 19 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
20 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
CREDOPHAR from Gent, company number BE0849730193, closed financial year 2025 with a result of € 51,670 after tax. For that financial year CREDOPHAR recorded a gross margin of € 257,722 and equity of € 1.9 million. Compared with financial year 2024, the result moved from € -182,309 to € 51,670. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 26, 2026.
€ 1.9 million
▲ 3% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 51,670
▲ still € 182,309 loss in 2024
Profit after tax over the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 1.9 million.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 104,292
▼ 59% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 50,460
▼ 26% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 1,111,605 | € 514,412 | € 109,990 | € 257,722 | ▲ 134% |
| Profit after taxes | € 320,180 | € 200,688 | € -182,309 | € 51,670 | ▲ € 233,979 |
| Equity | € 1,860,471 | € 2,061,159 | € 1,878,850 | € 1,930,520 | ▲ 3% |
| Total debts | € 6,649,039 | € 5,572,052 | € 5,761,601 | € 5,910,208 | ▲ 3% |
| Cash | € 1,086,341 | - | - | - | |
| Retained profit | € 1,839,950 | € 2,040,638 | € 1,858,328 | € 1,909,998 | ▲ 3% |
| Bank debt | € 0 | € 66 | € 0 | € 0 | |
| Balance sheet total | € 8,509,511 | € 7,633,211 | € 7,640,451 | € 7,840,727 | ▲ 3% |
| Employees (FTE) | 4.7 | - | - | - |
Key figures of CREDOPHAR, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to CREDOPHAR?
What happened at CREDOPHAR in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 51,670. filed late Source: NBB ↗
- Aquitania BV stepped down as director. NBB
- MD Consult BV stepped down as director. NBB
- Aquitania BV became a director. NBB
- MD Consult BV became a director. NBB
- New establishment in Gent. KBO
- Start of the company according to the CBE. KBO
In short
From € 320,180 profit in 2022 to € 51,670 profit in 2025.
Paid € 266,581 in corporate taxes since 2022.
Best year ever: 2022, with € 320,180 profit.
On average € 236,500 of value added per employee in 2022.
A new publication or filing at CREDOPHAR? We notify you, reason included.
Follow CREDOPHARDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Ceres Pharma comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
CREDOPHARThe shares are held by Ceres Pharma (100%). It owns 100% of Labophar itself.
Directors
According to the 2025 annual accounts
Director · represented by Anja Imschoot
Also active at: Ceres Pharmaceuticals, VESALE PHARMACEUTICA, b+pharma Belgium, DGPharma, Labophar, 2PHARMA HOLDING, MD Pharma, GLOBIFER INTL +1 more
since 2021 · until 2026
Director · represented by Mario Debel
Also active at: Ceres Pharmaceuticals, VESALE PHARMACEUTICA, 2PHARMA HOLDING, MD Pharma, Azur Medical, AUGMENTED ANATOMY, GLOBIFER INTL, 2PHARMA
since 2021 · until 2026
Shareholders
100%
Participations
100%
Establishments
Establishment units
Physical locations of this company
Kortrijksesteenweg 1091 box B
9051 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.
All companies at this address →Ceres Pharmaceuticals same network
€ 14.6 million revenue · 2025
What's Cooking Group
KOUTERLOS
€ 55,337 gross margin · 2024
b+pharma Belgium same network
€ 287,023 gross margin · 2025
DGPharma same network
€ 94,120 gross margin · 2024
+15 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
COMBELL-AS, BE
Website info
Features
Security
Details
- Company number
- 0849.730.193
- VAT number
- BE 0849.730.193
- Registered office
- Kortrijksesteenweg 1091 bus B, 9051 Gent
- Names & denominations
- CREDOPHAR
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 16 October 2012
- Peppol
- Active · Active since 17 Jul 2025
- Contact
- credophar.be [email protected]
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Handelsbemiddeling in de groothandel in andere specifieke goederen